Skip to content

Hip DAA Closure Techniques

Direct Anterior Approach of the Hip and Variations in Wound Complications Using Different Closure Techniques

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06006572
Enrollment
172
Registered
2023-08-23
Start date
2023-03-01
Completion date
2024-10-30
Last updated
2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Replacement, Wound Complication

Brief summary

This study aims to analyze the difference in rates of wound complications using two different closure techniques in Direct anterior approach for primary total hip replacement.

Detailed description

The use of the direct anterior approach (DAA) for primary total hip arthroplasty (THA) has been increasingly popular but there has been a reported increased risk of wound complications compared with a posterior approach. Wound complications can lead to increased length of stay, reoperation procedures (i.e., irrigation and debridement), patient dissatisfaction, extra visits, readmissions, increased risk of periprosthetic joint infection and overall increased costs.

Interventions

PROCEDUREwound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive

wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive

PROCEDUREwound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive

wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive

Sponsors

Rothman Institute Orthopaedics
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients older than 18 years old that will undergo THA via DAA

Exclusion criteria

* Previous hip arthroplasty surgeries or scars * THA secondary to oncologic or traumatic etiologies * BMI ≥ 40 * uncontrolled diabetes (measured by a Hgb A1c above 8) * reported allergy to skin adhesive

Design outcomes

Primary

MeasureTime frameDescription
Wound complications90 daysAssessed using photographic documentation of the wound
Participant satisfaction90 daysassessed using the POSAS (patient and observer scar assessment scale) questionnaire

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026